A Phase 3 interventional study of CB-03-01 cream, 1% in Acne Vulgaris, sponsored by Cassiopea SpA. Completed at 74 sites in 7 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2020-11-17.
Sponsored by Cassiopea SpA · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.
Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 5th largest by enrollment, is one of 3 that started in 2016, is one of 5 in phase 3, and was the 5th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:
Pak Emirates Military Hospital · Sites in Pakistan
Ages 12–55
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Sites in China
Ages 12+
Allied Hospital Faisalabad · Sites in Pakistan
Ages 15+
Khyber Teaching Hospital
Ages 12–35
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Ages 12+
By country, each count listing its studies:
Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 5 · Phase 4 7
First in 2012; this study’s year is marked. 3 started in 2016.
This study's enrollment of 609 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 50 across the 19 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 19 have an industry lead sponsor. The 8 most frequent:
Cassiopea SpA is the lead sponsor of 7 studies on the registry; none are open to participants now.
Cassiopea SpA has 4 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
3 of the studies testing clascoterone in Acne Vulgaris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07673094Khyber Teaching HospitalComparison of Topical Clascoterone and Adapalene for Mild Acne Vulgaris | 2027-02 |
| NCT07883538Pak Emirates Military HospitalComparison of Topical Clascoterone 1% Cream Versus Adapalene 0.1% Cream in the Treatment of Mild-to-Moderate Acne Vulgaris | 2027-04-30 |
| NCT07881315Allied Hospital FaisalabadClascoterone Versus Clindamycin Added to Adapalene/Benzoyl Peroxide for Moderate Facial Acne | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies testing clascoterone in Acne Vulgaris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine the long-term safety of CB-03-01 cream, 1% applied twice daily for an additional nine months in study participants with acne vulgaris that participated in the Phase 3 pivotal studies for a total treatment of up to 12 months.
This was a multicenter, open label, long-term extension study for CB-03-01 cream, 1% focused on safety in male and female participants, 9 years or older who completed one of the Phase 3 pivotal studies [CB-03-01/25 and CB-03-01/26]. Participants applies the active medication (CB-03-01 cream, 1%) twice daily to the entire face and, if designated by investigator AND desired by the participant, truncal acne for nine additional months of treatment. Thus, overall participants were exposed to CB-03-01 cream, 1% for a total treatment of up to 12 months (0 or 3 months in the Phase 3 pivotal study and an additional nine months in this long-term safety study).
Participants treated facial acne per protocol for nine months. Treatment of truncal acne was discussed by the investigator and participant. Treatment on the face and/or trunk was discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area (i.e., face and trunk).
Participants were rolled over from the Phase 3 pivotal studies [CB-03-01/25 and CB-03-01/26] into this long-term, safety study in order to achieve at least 300 participants on-study at 6 months and 100 participants on-study at 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CB-03-01 (cortexolone 17α-propionate) Cream, 1%, applied twice daily to whole face (about 1 gram) and affected areas of trunk (if applicable) for up to an additional 9 months. Over the course of the study, treatment on the face and/or trunk may be discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area.
Drug: CB-03-01 cream, 1%
Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
Also known as: cortexolone 17α-propionate, clascoterone (USAN, INN)
Number of Participants With Any Local and Systemic Treatment Emergent Adverse Events
Number of participants with any local and systemic treatment emergent AEs (TEAEs)
Time frame: up to 52 weeks
There were 609 subjects who were rolled over (i.e., enrolled) from the two Phase 3 pivotal studies (CB-03-01/25 \[NCT02608450\] and CB-03-01/26 \[NCT02608476\]) into this long-term, safety study. However, two (2) subjects in the original vehicle cream were not treated with test article and thus were excluded from the study population (Safety set).
| Milestone | CB-03-01 Cream, 1% | CB-03-01 Cream, 1% (Vehicle Arm) |
|---|---|---|
| Started | 317 | 290 |
| Completed | 179 | 168 |
| Not completed | 138 | 122 |
| Withdrew: Withdrawal by subject | 56 | 45 |
| Withdrew: Lost to follow-up | 49 | 41 |
| Withdrew: Lack of efficacy | 14 | 16 |
| Withdrew: Withdrawal by parent | 6 | 7 |
| Withdrew: Adverse event | 9 | 0 |
| Withdrew: Noncompliance with study drug | 1 | 4 |
| Withdrew: Pregnancy | 1 | 2 |
| Withdrew: Recovery | 1 | 2 |
| Withdrew: Progressive disease | 1 | 0 |
| Withdrew: Technical problems | 0 | 1 |
| Withdrew: Moved abroad and unable to continue | 0 | 3 |
| Withdrew: Stopped test article application | 0 | 1 |
Number of participants with any local and systemic treatment emergent AEs (TEAEs)
| Participants | CB-03-01 Cream, 1% | CB-03-01 Cream, 1% (Vehicle Arm) |
|---|---|---|
| Number of Participants With Any Local and Systemic Treatment Emergent Adverse Events | 58 | 52 |
Collected over Treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) were collected from the time the subject exited the pivotal study (i.e., Week 13 or day 1 of the Long-term extension study) and up to 52 weeks after entry into the pivotal study (i.e., up to week 39 or early termination of the long term extension study).. Non-serious events are listed at a 0.7% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CB-03-01 Cream, 1% | 0/317 (0%) | 3/317 (0.9%) | 21/317 (6.6%) |
| CB-03-01 Cream, 1% (Vehicle Arm) | 0/290 (0%) | 3/290 (1%) | 17/290 (5.9%) |
| Event | CB-03-01 Cream, 1% | CB-03-01 Cream, 1% (Vehicle Arm) |
|---|---|---|
| FatigueGeneral disorders | 0/317 | 1/290 |
| Abortion inducedSurgical and medical procedures | 0/317 | 1/290 |
| Coronary artery dissectionVascular disorders | 0/317 | 1/290 |
| DepressionPsychiatric disorders | 1/317 | 0/290 |
| Suicide attemptPsychiatric disorders | 1/317 | 0/290 |
| Gastroenteritis eosinophilicGastrointestinal disorders | 1/317 | 0/290 |
| DizzinessNervous system disorders | 1/317 | 0/290 |
| Event | CB-03-01 Cream, 1% | CB-03-01 Cream, 1% (Vehicle Arm) |
|---|---|---|
| NasopharyngitisInfections and infestations | 6/317 | 10/290 |
| Upper respiratory tract infectionInfections and infestations | 7/317 | 1/290 |
| Respiratory tract infection viralInfections and infestations | 1/317 | 4/290 |
| Application site acneGeneral disorders | 4/317 | 0/290 |
| SinusitisInfections and infestations | 3/317 | 2/290 |
Safety population defined as all subjects who applied at least one dose of test article.
| Age, Continuous(years) | CB-03-01 Cream, 1% | CB-03-01 Cream, 1% (Vehicle Arm) | Total |
|---|---|---|---|
| Mean | 19.2 ± 5.8 | 19.3 ± 6.7 | 19.2 ± 6.3 |
| Sex: Female, Male(Participants) | CB-03-01 Cream, 1% | CB-03-01 Cream, 1% (Vehicle Arm) | Total |
|---|---|---|---|
| Female | 198 | 183 | 381 |
| Male | 119 | 107 | 226 |
| Ethnicity (NIH/OMB)(Participants) | CB-03-01 Cream, 1% | CB-03-01 Cream, 1% (Vehicle Arm) | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 15 | 42 |
| Not Hispanic or Latino | 290 | 275 | 565 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CB-03-01 Cream, 1% | CB-03-01 Cream, 1% (Vehicle Arm) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 6 | 8 | 14 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 3 |
| Black or African American | 17 | 18 | 35 |
| White | 283 | 256 | 539 |
| More than one race | 4 | 6 | 10 |
| Unknown or Not Reported | 4 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2016 to primary completion in Aug 2018, 29 months.
Results were first posted in Nov 2020, 2 years 2 months after primary completion. A results delay was requested in Jun 2019.
Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 29 months is above that.
Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clascoterone
Cassiopea SpA